Skip to main content
Clinical Trials/NCT05686707
NCT05686707
Recruiting
Not Applicable

Characterization of Different Phenotypes of Microvascular Dysfunction and Their Impact on Angina Severity in Patients With Chronic Angina in the Absence of Obstructive Coronary Artery Disease

Federico II University1 site in 1 country400 target enrollmentJuly 18, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Angina CCS Classe II-IV - IMR, RFR, FFR,CFR
Sponsor
Federico II University
Enrollment
400
Locations
1
Primary Endpoint
(SAQ-7)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The aim of the present study will be to identify different phenotypes of microvascular dysfunction and their associations with the severity of anginal symptoms assessed through the Seattle Angina Questionnaire(SAQ-7).

Detailed Description

After administration of unfractionated heparin (100UI/Kg), a special pressure guide (Pressure Wire X, Abbott), equipped with a distal sensor capable of measuring pressure and temperature, will be introduced inside the anterior descending branch (IVA) of the left coronary artery and hyperemia will be induced by intravenous infusion of adenosine. The IMR will be calculated using the thermodilution technique, and is given by the product between the mean distal pressure, in the left anterior descending coronary artery, and the mean transit time (Tmn) during maximal hyperemia. During the procedure, additional coronary physiological indices will be calculated such as: * Quiescent full cycle flow ratio (RFR), - Fractional flow reserve (FFR), * Coronary flow reserve (CFR) In order to identify different phenotypes of microvascular dysfunction, as follows: * Phenotype A: Patients with IMR\>25, CFR \<2 and FFR\>0.80 (concordant pure-microvascular pathological results) * Phenotype B: patients with IMR\>25, CFR\>2 and FFR\>0.80 (increased microvascular hyperemic resistance, maintenance of microvascular reactivity) * Phenotype C: Patients with IMR 25, CFR 2 and FFR\>0.80 (normal hyperemic resistance and reduced reactivity) All these phenotypes can also be combined with pathological FFR measures (\<0.80) (phenotypes A1, B1, C1).

Registry
clinicaltrials.gov
Start Date
July 18, 2022
End Date
June 30, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Federico II University
Responsible Party
Principal Investigator
Principal Investigator

Giovanni Esposito

Full Professor

Federico II University

Eligibility Criteria

Inclusion Criteria

  • Patients who meet all of the following criteria will be considered for study participation:
  • Age ≥18 and \<85 years. Chronic coronary syndrome (including patients with anginal equivalents) Angina CCS class II-IV Evidence of inducible reversible ischemia in noninvasive trials
  • Availability of the following measurements:
  • Microvascular resistance index (IMR)
  • Quiescent full cycle flow ratio (RFR),
  • fractional flow reserve (FFR),
  • Coronary flow reserve (CFR) Willingness to participate and sign the informed consent document prior to the procedure.

Exclusion Criteria

  • At least one of the following:
  • Pregnancy or breastfeeding. Medical or psychological conditions that would compromise proper and orderly participation.
  • Left ejection fraction less than 30% Prior coronary artery bypass surgery (CABG) Decompensated congestive heart failure (CHF) Chronic or acute renal failure with creatinine \>2mg/dl Severe valve disease Patients with comorbidities limiting life expectancy to less than one year.

Outcomes

Primary Outcomes

(SAQ-7)

Time Frame: 12 months

Identify different phenotypes of microvascular dysfunction and their associations with anginal symptom severity assessed through the Seattle Angina Questionnaire (SAQ-7).

Secondary Outcomes

  • characterization of the severity of angina(12 months)

Study Sites (1)

Loading locations...

Similar Trials